1. HISTOGEN - 2018 Awaiting phase 2 trial results
2. SAMUMED - 2018 Phase 2 results avail 3/16
3. KYTHERA\BIMATOPROST\SETI – 2019 A WILD GUESS. BIG MYSTERY.
4. REPLICEL 2021 IN GERMANY. MAYBE 2019 IN JAPAN
5. CB 03 01 - 2021
1. HISTOGEN - 2018 Awaiting phase 2 trial results
2. SAMUMED - 2018 Phase 2 results avail 3/16
3. KYTHERA\BIMATOPROST\SETI – 2019 A WILD GUESS. BIG MYSTERY.
4. REPLICEL 2021 IN GERMANY. MAYBE 2019 IN JAPAN
5. CB 03 01 - 2021
**** if that's all I'd probably need to use a combination of all those treatments. I don't understand the science of hair loss but the from the reactions of people that do, those do not seem like anything to get excited about.
Histogen - Decent results on the ONE before/after sample
Samumed - Actually pretty hopeful
Seti - Not doing much for me at around ~300mg
Replicel - Can be great or can be ****
CB - Seems good but 2021?! I've read the reason for this is that they are trailing its for acne first (which is bull****) but if it is released as an acne treatment, will it become more accessible as a hair treatment?
And there are also JAK inhibitors from Christiano. Not sure what the consensus is on that. Then you have researches from Tsuji and others, but those are so far away, it's not even worth looking forward to.
Basically, if you're on these forums now and Replicel is not some sort of miracle, our best hope is advancements in hair transplant technology.
Because, in all likelihood, they have to run a phase III trial, finalize production/distribution, etc. The trial itself is another year, plus all the planning and such that goes into it. I actually think it would be closer to 2019 since a Phase III probably wouldn't start until the 2nd half of this year (again, this is all assuming they move forward).
I think people are being really optimistic with the 21st century cures act...even if Samumed qualified to skip phase III (which they won't if you read the bill), the act first has to pass, get signed into order and then they'd need to plan/confirm/assemble the specific review processes and teams that would be required to oversee the approvals.
Look at the delays Japan is facing with their comparable bill.